Multiple myeloma study yields positive results for GSK

GSK’s pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916) involved 196 patients with relapsed multiple myeloma, who were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody. The study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin. The safety and tolerability profile was consistent with that observed in DREAMM-1. Further studies are testing the effect of belantamab mafodotin as third-line monotherapy in relapsed/refractory multiple myeloma and as a combination treatment in the first and second line setting as part of the broader DREAMM clinical development programme.
Chief Scientific Officer and President R&D, GSK, Dr Hal Barron, said: “I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment. We are on track to file belantamab mafodotin later this year and continue to investigate how it could help even more patients with this disease.”